ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 936

Autoimmune Diseases: Declining Mortality Between 1999 and 2008 However Continuing to be a Leading Cause of Death in Children-A 10-Year Retrospective Review

Eric Y. Yen1 and Deborah K. McCurdy2, 1Pediatrics/Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, 2Pediatric Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: autoimmune diseases, death, morbidity and mortality, pediatric rheumatology and pediatrics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Autoimmune diseases are chronic illnesses that cause significant and chronic disability in children and may lead to death. Using mortality data from 1995, Walsh and Rau showed that autoimmune disease deaths were the leading causes of death among young women. The objective of this study is to examine the trends in crude mortality rate in children for autoimmune diseases in the United States.

Methods: We selected 24 autoimmune diseases (Table 1) chosen by Jacobson et al using the criteria of Rose and Bona, who defined autoimmune diseases as having direct proof or indirect evidence of autoimmune pathogenesis. Every autoimmune disease was classified with ICD-10 diagnosis code(s). Using the information provided by the Center for Disease Control (CDC), we reviewed all mortality data from the period of 1999-2008 in 3 year intervals. CDC reports that >99% of all deaths in the United States are registered. Each death certificate that lists an autoimmune disease as the underlying cause of death was identified and counted. Age groups, crude mortality rates per 100,000 persons (=number of deaths/population*100,000), and total mortality changes (percent change) between 1998 and 2008 were defined and calculated. We also compared the number of autoimmune disease deaths to the top ten leading causes of death by age in 2008.

 

Addison’s disease (E27.1, E27.2, E27.4)

Autoimmune hemolytic anemia (D59.1)

Chronic active hepatitis (K73)

Glomerulonephritis (N00, N01, N03, N05, N18)

Goodpasture’s syndrome (M31.0)

Graves’ disease/hyperthyroidism (E05.0)

Idiopathic thrombocytopenia purpura (D69.3)

Insulin dependent diabetes (E10)

Multiple sclerosis (G35)

Myasthenia gravis (G70.0)

Myocarditis (I40.1, I40.8, I40.9, I51.4, I51.8)

Pemphigus vulgaris (L10.0)

Pernicious anemia (D51.0)

Relapsing polychondritis (M94.1)

Polymyositis/dermatomyositis (M33)

Primary biliary cirrhosis (K74.3)

Rheumatic fever and Rheumatic heart disease

(I00, I01, I02, I05, I06, I07, I08, I09)

Rheumatoid arthritis (M05, M06, M08)

Scleroderma (M34, L94.0, L94.1)

Sjogren’s (M35.0)

Systemic lupus erythematosus (M32)

Thyroiditis (E06.3)

Uveitis (H20.0, H20.1, H20.8, H20.9, H30)

Vitiligo (L80)

Table 1. Autoimmune Diseases (ICD-10 codes).

Results: Table 2 presents the crude mortality rates of autoimmune diseases from 1999, 2002, 2005, and 2008 and the percent change between 1999 and 2008. Mortality rates decreased from 5% to 33% in all age groups except for children younger than 5 years old. The absolute numbers of autoimmune disease death did not increase over time. Likewise, mortality rates for all causes decreased for all age group under 20 years old. Despite a sharp decline in mortality rates, autoimmune diseases continue to be a leading cause of death among children (Table 3).

 

 

Age

Crude Mortality Rate (=Deaths/Population*100,000)

% Change Between 1999 and 2008

1999

2002

2005

2008

Autoimmune Diseases

1-4

5-9

10-14

15-19

20-24

0.33

0.19

0.26

0.60

1.05

0.22

0.11

0.21

0.56

0.97

0.26

0.14

0.21

0.49

1.01

0.35

0.18

0.19

0.40

0.93

6.06%

-5.26%

-26.92%

-33.33%

-11.43%

All Causes of Death

1-4

5-9

10-14

15-19

20-24

34.22

16.86

20.39

68.6

90.78

31.19

15.17

19.55

67.79

95.15

29.36

14.52

18.05

65.13

97.59

28.37

12.47

15.7

57.67

93.98

-17.10%

-26.04%

-23.00%

-15.93%

3.53%

Table 2. Trends in crude mortality rates for autoimmune diseases and all causes of death. Crude mortality rates are expressed per 100,000 persons.

 

Age

Relative Rank

1-4

#8

5-9

#10

10-14

#9

15-19

#6

20-24

#6

Table 3. Relative ranking of autoimmune disease deaths when compared to the official 10 leading causes of death in 2008.

Conclusion: Although mortality rates from autoimmune diseases appear to be declining in children 5-20 years of age, autoimmune diseases continue to rank within the top ten leading causes of death.

 


Disclosure:

E. Y. Yen,
None;

D. K. McCurdy,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/autoimmune-diseases-declining-mortality-between-1999-and-2008-however-continuing-to-be-a-leading-cause-of-death-in-children-a-10-year-retrospective-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology